reportlinker.com/p0191857/Pharmaceuticals—Global-Group-of-Eight-G8-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Includes a five-year forecast of the industry
Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 49.1% in 2011.
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).
Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.
Table 1: G8 pharmaceuticals industry, revenue($bn), 2007-16 16
Table 2: G8 Pharmaceuticals industry, revenue by country (%), 2011 17
Table 3: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11 18
Table 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16 19
Table 85: Johnson & Johnson: key facts 140
Table 86: Johnson & Johnson: key financials ($) 141
Table 87: Johnson & Johnson: key financial ratios 141
Table 88: Pfizer Inc.: key facts 143
Table 89: Pfizer Inc.: key financials ($) 144
Table 90: Pfizer Inc.: key financial ratios 144
Table 91: AstraZeneca PLC: key facts 146
Table 92: AstraZeneca PLC: key financials ($) 147
Table 93: AstraZeneca PLC: key financial ratios 148
Table 94: GlaxoSmithKline Plc: key facts 150
Table 95: GlaxoSmithKline Plc: key financials ($) 151
Table 96: GlaxoSmithKline Plc: key financials () 152
Table 97: GlaxoSmithKline Plc: key financial ratios 152
Table 98: Novartis AG: key facts 154
Table 99: Novartis AG: key financials ($) 155
Table 100: Novartis AG: key financial ratios 155
Table 101: Chiesi Farmaceutici S.P.A.: key facts 157
Table 102: Menarini Group, The: key facts 159
Table 103: Takeda Pharmaceutical Company Limited: key facts 160
Table 104: Takeda Pharmaceutical Company Limited: key financials ($) 161
Table 105: Takeda Pharmaceutical Company Limited: key financials () 161
Table 106: Takeda Pharmaceutical Company Limited: key financial ratios 161
Table 107: Daiichi Sankyo Co., Ltd.: key facts 163
Table 108: Daiichi Sankyo Co., Ltd.: key financials ($) 164
Table 109: Daiichi Sankyo Co., Ltd.: key financials () 164
Table 110: Daiichi Sankyo Co., Ltd.: key financial ratios 164
Table 111: Mitsubishi Tanabe Pharma Corporation: key facts 166
Table 112: Mitsubishi Tanabe Pharma Corporation: key financials ($) 167
Table 113: Mitsubishi Tanabe Pharma Corporation: key financials () 167
Table 114: Mitsubishi Tanabe Pharma Corporation: key financial ratios 167
Table 115: Pharmstandard OJSC: key facts 169
Table 116: Pharmstandard OJSC: key financials ($) 169
Table 117: Pharmstandard OJSC: key financials (RUB) 170
Table 118: Pharmstandard OJSC: key financial ratios 170
Table 119: Sanofi: key facts 172
Table 120: Sanofi: key financials ($) 173
Table 121: Sanofi: key financials (€) 173
Table 122: Sanofi: key financial ratios 173
Table 123: Bayer AG: key facts 175
Table 124: Bayer AG: key financials ($) 176
Table 125: Bayer AG: key financials (€) 176
Table 126: Bayer AG: key financial ratios 177
Table 127: Merck & Co., Inc.: key facts 179
Table 128: Merck & Co., Inc.: key financials ($) 180
Table 129: Merck & Co., Inc.: key financial ratios 180
Nicolas Bombourg
Reportlinker
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker